1. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10.

2. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010;153:800-8.

3. Rye KA, Barter PJ. Cardioprotective functions of HDLs. J Lipid Res 2014;55:168-79.

4. Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol 2002;13:285-8.

5. Kosmas CE, Martinez I, Sourlas A, Bouza KV, Campos FN, et al. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. Drugs Context 2018;7:212525.

6. Favari E, Thomas MJ, Sorci-Thomas MG. High-density lipoprotein functionality as a new pharmacological target on cardiovascular disease: unifying mechanism that explains high-density lipoprotein protection toward the progression of atherosclerosis. J Cardiovasc Pharmacol 2018;71:325-31.

7. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014;371:2383-93.

8. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011;8:222-32.

9. Tailleux A, Fruchart JC. HDL heterogeneity and atherosclerosis. Crit Rev Clin Lab Sci 1996;33:163-201.

10. Kosmas CE, Christodoulidis G, Cheng JW, Vittorio TJ, Lerakis S. High-density lipoprotein functionality in coronary artery disease. Am J Med Sci 2014;347:504-8.

11. Kontush A, Lhomme M, Chapman MJ. Unraveling the complexities of the HDL lipidome. J Lipid Res 2013;54:2950-63.

12. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006;116:3090-100.

13. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-56.

14. Kontush A, Lhomme M, Chapman MJ. Unraveling the complexities of the HDL lipidome. J Lipid Res 2013;54:2950-63.

15. Tölle M, Huang T, Schuchardt M, Jankowski V, Prüfer N, et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res 2012;94:154-62.

16. Jahangiri A. High-density lipoprotein and the acute phase response. Curr Opin Endocrinol Diabetes Obes 2010;17:156-60.

17. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758-67.

18. Yamamoto K, Isogai Y, Sato H, Taketomi Y, Murakami M. Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics. Anal Bioanal Chem 2011;400:1829-42.

19. Kar S, Patel MA, Tripathy RK, Bajaj P, Suvarnakar UV, et al. Oxidized phospholipid content destabilizes the structure of reconstituted high density lipoprotein particles and changes their function. Biochim Biophys Acta 2012;1821:1200-10.

20. Kameda T, Ohkawa R, Yano K, Usami Y, Miyazaki A, et al. Effects of myeloperoxidase-induced oxidation on antiatherogenic functions of high-density lipoprotein. J Lipids 2015;2015:592594.

21. Chen C, Khismatullin DB. Oxidized low-density lipoprotein contributes to atherogenesis via co-activation of macrophages and mast cells. PLoS One 2015;10:e0123088.

22. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012;51:314-24.

23. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001;42:1308-17.

24. Salazar J, Olivar LC, Ramos E, Chávez-Castillo M, Rojas J, et al. Dysfunctional high-density lipoprotein: an innovative target for proteomics and lipidomics. Cholesterol 2015;2015:296417.

25. Chait A, Han CY, Oram JF, Heinecke JW. Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005;46:389-403.

26. Nobécourt E, Jacqueminet S, Hansel B, Chantepie S, Grimaldi A, et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 2005;48:529-38.

27. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000;43:312-20.

28. Hoang A, Murphy AJ, Coughlan MT, Thomas MC, Forbes JM, et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 2007;50:1770-9.

29. Nobécourt E, Tabet F, Lambert G, Puranik R, Bao S, et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2010;30:766-72.

30. He BM, Zhao SP, Peng ZY. Effects of cigarette smoking on HDL quantity and function: implications for atherosclerosis. J Cell Biochem 2013;114:2431-6.

31. McMorrow AM, O’Reilly M, Connaughton RM, Carolan E, O’Shea D, et al. Obesity and dietary fat modulate HDL function in adolescents: results from a cross-sectional analysis and a randomized, placebo-controlled, crossover trial. FASEB J 2016;30:130.

32. Nicholls SJ, Lundman P, Harmer JA, Cutri B, Griffiths KA, et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J Am Coll Cardiol 2006;48:715-20.

33. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008;51:634-42.

34. Qi Y, Fan J, Liu J, Wang W, Wang M, et al. Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study. J Am Coll Cardiol 2015;65:355-63.

35. Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J 2017;38:2478-86.

36. Hirata A, Sugiyama D, Watanabe M, Tamakoshi A, Iso H, et al. Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: the EPOCH-JAPAN study. J Clin Lipidol 2018;12:674-84.

37. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127-35.

38. Ogura M, Hori M, Harada-Shiba M. Association between cholesterol efflux capacity and atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2016;36:181-8.

39. Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L, et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 2014;20:193-203.

40. Carnuta MG, Stancu CS, Toma L, Sanda GM, Niculescu LS, et al. Dysfunctional high-density lipoproteins have distinct composition, diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients. Sci Rep 2017;7:7295.

41. Kratzer A, Giral H, Landmesser U. High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease. Cardiovasc Res 2014;103:350-61.

42. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011;121:2693-708.

43. Angeloni E, Paneni F, Landmesser U, Benedetto U, Melina G, et al. Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J 2013;34:3557-62.

44. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92.

Vessel Plus
ISSN 2574-1209 (Online)
Follow Us


All published articles are preserved here permanently:


All published articles are preserved here permanently: